These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7628177)

  • 21. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.
    Pieterson EA
    J Clin Pharmacol; 1992 Oct; 32(10):889-96. PubMed ID: 1447395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Bull (Edinb); 1981 Nov; 39(6):356-66. PubMed ID: 7035401
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

  • 27. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.
    Lexchin J
    Healthc Policy; 2016 Nov; 12(2):65-75. PubMed ID: 28032825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
    Hooimeyer A; Bhasale A; Perry L; Fabbri A; Mohammad A; McEwin E; Mintzes B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00680. PubMed ID: 33169534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use and reported adverse effects of new chemical entities.
    Kennedy DL; Goetsch RA; Dreis MW
    Am J Hosp Pharm; 1989 Mar; 46(3):558-65. PubMed ID: 2719041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New chemical entities and their market penetration in Finland during the years 1996 through 2005.
    Martikainen JE; Enlund H
    Clin Ther; 2009 Mar; 31(3):668-76. PubMed ID: 19393857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Food and drug administration regulation of drugs that raise blood pressure.
    Blankfield RP; Iftikhar IH
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):5-8. PubMed ID: 24803642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decline in the Development of New Anesthetics.
    Vlassakov KV; Kissin I
    Trends Pharmacol Sci; 2016 May; 37(5):344-352. PubMed ID: 26922254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 40. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.
    Rawson NS
    Can J Clin Pharmacol; 2002; 9(2):73-8. PubMed ID: 12172587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.